Diabetes obesity & metabolism, 1462-8902


View graph of relations

Related Publications
  1. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

    Dekkers, C. C. J., Sjostrom, C. D., Greasley, P. J., Cain, V., Boulton, D. W. & Heerspink, H. J. L., 13-Sep-2019, In : Diabetes obesity & metabolism. 7 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality

    Kanbay, M., Ertuglu, L. A., Afsar, B., Ozdogan, E., Kucuksumer, Z. S., Ortiz, A., Covic, A., Kuwabara, M., Cherney, D. Z. I., van Raalte, D. H. & de Zeeuw, D., 12-Jul-2019, In : Diabetes obesity & metabolism. 16 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  3. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

    Koomen, J. V., Heerspink, H. J. L., Schrieks, I. C., Schwartz, G. G., Lincoff, A. M., Nicholls, S. J., Svensson, A., Wedel, H., Weichert, A., Grobbee, D. E. & Stevens, J., 1-Oct-2019, In : Diabetes obesity & metabolism. 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (53) »

ID: 4952827